Human Brain Cancer Peripheral Blood Mononuclear Cells

Description

Human Brain Cancer Peripheral Blood Mononuclear Cells are mainly derived from the patient’s peripheral blood. They are represent a heterogeneous cell population, including lymphocytes (T cells, B cells, NK cells) and monocytes. Morphologically, PBMCs are round or oval. PBMCs are mainly involved in immune surveillance and tumor microenvironment regulation in brain cancer: CD8+ T cells can recognize tumor antigens, NK cells mediate natural killing, and monocytes differentiate into tumor-associated macrophages (TAMs), which may have both tumor-promoting and tumor-suppressive functions.

Application

• Human Brain Cancer Peripheral Blood Mononuclear Cells can be used for immunotherapy research, such as in vitro expansion and functional evaluation of CAR-T cell therapy, or target screening to enhance anti-tumor immune responses. In addition, immunophenotyping of PBMCs (such as PD-1 and CTLA-4 expression levels) can assess the patient’s immunosuppressive status and guide immune checkpoint inhibitor therapy.